TACSTD2 and neoplasm: While CMS1/MSI-high are biomarkers of ICI response in CRC,23,24 liver cancer lacks well-defined biomarkers for ICI response.25 Of all the tumor types, liver cancer displayed the most robust increase in immune infiltration and increased prevalence of T-cell-inflamed tumor for TACSTD2-high compared to TACSTD2-low.